Neuronal gene expression is modulated by activity via calcium-permeable receptors such as NMDA receptors (NMDARs). While gene expression changes downstream of evoked NMDAR activity have been well studied, much less is known about gene expression changes that occur under conditions of basal neuronal activity. In mouse dissociated hippocampal neuronal cultures, we found that a broad NMDAR antagonist, AP5, induced robust gene expression changes under basal activity, but subtype-specific antagonists did not. While some of the gene expression changes are also known to be downstream of stimulated NMDAR activity, others appear specific to basal NMDAR activity. The genes altered by AP5 treatment of basal cultures were enriched for pathways related to class IIa histone deacetylases (HDACs), apoptosis, and synapse-related signaling. Specifically, AP5 altered the expression of all three class IIa HDACs that are highly expressed in the brain, HDAC4, HDAC5, and HDAC9, and also induced nuclear accumulation of HDAC4. HDAC4 knockdown abolished a subset of the gene expression changes induced by AP5, and led to neuronal death under long-term tetrodotoxin or AP5 treatment in rat hippocampal organotypic slice cultures. These data suggest that basal, but not evoked, NMDAR activity regulates gene expression in part through HDAC4, and, that HDAC4 has neuroprotective functions under conditions of low NMDAR activity.
Introduction
NMDA receptors (NMDARs) play a fundamental role in many brain processes and are implicated in a variety of nervous system disorders (Paoletti et al., 2013; Zhou and Sheng, 2013) . While resting NMDARs are typically inactive due to Mg 2ϩ blockade, neuronal depolarization leads to a reduction of Mg 2ϩ inhibition, enabling NMDAR activation by glutamate. Gene expression changes downstream of NMDAR activation are critical for normal nervous system physiology and are also relevant in pathological situations, such as excitotoxicity (Zhang et al., 2007; Hagenston and Bading, 2011) .
NMDAR signaling has generally been studied by using NMDAR agonists or GABA A receptor (GABA A R) antagonists, both of which strongly stimulate NMDARs above their basal level of activity (Sala et al., 2000; Hardingham et al., 2002; Zhang et al., 2007) . However, data exist to suggest that NMDARs play a significant role in neuronal function under basal as well as hyperexcited conditions. For example, the inhibition of basal NMDAR activity rapidly and sustainably potentiates excitatory synaptic strength (Sutton et al., 2006; Autry et al., 2011) , possibly underlying the apparent antidepressant effects of NMDAR antagonists (Zarate et al., 2006; Autry et al., 2011) . Additionally, basal NMDAR activity is required for ␤-Amyloid-induced synaptic deficits (Nakagawa et al., 2004; Shankar et al., 2008; Wei et al., 2010; Jiao and Li, 2011; Kessels et al., 2013) , and an NMDAR antagonist, memantine, is used to treat Alzheimer's disease (Reisberg et al., 2003) . As the effect of NMDAR activation is highly context dependent (Sala et al., 2000; Hardingham et al., 2002; Liu et al., 2004; Kim et al., 2005; Zhang et al., 2007; Hardingham and Bading, 2010) , it is likely that basal NMDAR activity regulates a distinct downstream gene expression program compared with that of stimulated NMDAR activity. However, the exact transcriptional events downstream of basal NMDAR activity remain poorly characterized.
Chromatin modifications by histone deacetylases (HDACs) are known to regulate transcription in neurons (Haberland et al., 2009) . Mutations in the ataxia telangiectasia mutated gene in mice result in abnormal nuclear accumulation of HDAC4, abnormal histone acetylation, and cerebellar neurodegeneration . Additionally, the expression of a constitutively nuclear-localized HDAC4 mutant in mice leads to synaptic and learning deficits (Sando et al., 2012) . In humans, a variant in HDAC4 causing constitutive nuclear localization has been linked to a rare brachydactyly mental retardation syndrome (Williams et al., 2010) . While these data point to an important role for HDAC4 in the brain, its precise function and regulation are unclear.
Here we show that under conditions of basal activity, treatment of cultured neurons with a broad NMDAR antagonist, AP5, results in large-scale gene expression changes. Similar, but less robust, changes were observed after treatment with subtypeselective antagonists of NMDARs Ro25-6981 (Ro25) or NVP-AAM077 (NVP). Only a subset of these gene expression changes was previously known to be regulated by NMDAR signaling, suggesting that NMDAR signaling in basal and hyperactive conditions induces distinct transcriptional programs. We show that basal NMDAR activity regulates the expression of genes enriched in apoptosis-related signaling pathways, and additionally, regulates the expression of all three class IIa HDACs (HDAC4, HDAC5, and HDAC9) that are expressed in the brain (Haberland et al., 2009) . Knockdown of HDAC4 attenuated a subset of the AP5-induced gene expression changes and also led to neuronal death under long-term tetrodotoxin (TTX) or AP5 treatment. Together, these results suggest that HDAC4 plays an important role in regulating the expression of downstream targets of basal NMDAR signaling, and also highlight that HDAC4 has a neuroprotective role under conditions of low NMDAR activity.
Materials and Methods
Neuronal cultures and drug treatments. Whole hippocampi were dissected from embryonic day 15 (E15) to E16 C57BL/6 wild-type (WT) or GluN2A knock-out (KO) (Kadotani et al., 1996) mice (either sex) in ice-cold HBSS buffer before they were digested by papain. Cells were seeded at 180,000 cells/well in 12-well plates, and 450,000 cells/well in 6-well plates. Cells were grown in B27 neuron chow, which contains 97 ml of Neurobasal Medium (catalog #21103-049, Invitrogen), 2 ml of B27 Supplement (catalog #17504-044, Invitrogen), 0.5 mM glutamine, 12.5 M glutamate, and 100 U/ml penicillin/streptomycin (catalog #15141, Invitrogen). Neurons were maintained in a 37°C cell culture incubator with 5% CO 2 and fed once a week after plating with B27 chow without glutamate. NMDA 70 M was applied at 21 d in vitro (DIV) for 10 min after a 5 min preincubation of either vehicle, AP5 100 M, NVP 0.1 or 1 M (Auberson et al., 2002; Neyton and Paoletti, 2006) , or Ro25-4891 (Ro25) 1 M (Fischer et al., 1997) in a cell culture incubator.
Western blot. Neurons in 12-well plates were put on ice immediately after drug treatment and rinsed once with ice-cold PBS before they were lysed with 100 l of 1ϫ Tris-glycine SDS Western sample buffer per well. Lysates were shaken for 10 min at room temperature, followed by 10 min of boiling and 10 min of centrifugation at 140,000 ϫ g. Western blots were then performed using Tris-glycine SDS gels. The following antibodies were used in this study: (Kim et al., 2007) .
DNA constructs. All cDNAs were expressed using the pCAG vector (chicken ␤-actin promoter with CMV enhancer). shRNA constructs were annealed and inserted into the HindIII/BglII sites of pSUPER vector (Brummelkamp et al., 2002; Nelson et al., 2013) . The targeted cDNA sequences by shRNAs are as follows: pSUPER HDAC4-shRNA (shH4_1): 5Ј-GGTCATGCCAATCGCAAAT-3Ј; pSUPER HDAC4-shRNA_1 (shH4_2): 5Ј-GCTTCTGAAGCATGTGTTTCT-3Ј; and pSUPER Luciferase-shRNA (shLuc): 5Ј-CGTACGCGGAATACTTCGA-3Ј.
Lentivirus. shH4_1 and control shRNA targeting firefly luciferase were subcloned into the pFHSynGW backbone vector from pSuper with its original H1 promoter. GFP expression was driven by a human Synapsin I promoter in the same pFHSynGW vector (provided by Dr. Carlos Lois, Massachusetts Institute of Technology, Cambridge, MA). Lentiviral particles were produced as described previously (Lois et al., 2002) . The viral titer was estimated by serial dilution infections of HEK293 cells. Cultures were infected at DIV 14 and used 6 -7 d after infection.
Quantitative RT-PCR. Relative mRNA levels were determined using the QuantiTect SYBR-Green RT-PCR (reverse-transcription-PCR) kit (Qiagen) according to its instructions. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. Primers were purchased from Qiagen. Each RT-PCR was performed in duplicate. Expression levels were normalized to vehicle-treated samples and compared with a hypothetical mean of 1 using a one-sample or two-sample t test, as indicated.
Organotypic hippocampal slice culture, electrophysiology, and neuronal survival assay. Patch-clamp recordings were performed from CA1 pyramidal cells in organotypic hippocampal slice cultures dissected from postnatal day 6 (P6) to P7 Sprague-Dawley rats (of either sex; Kim et al., 2007) . DIV3 to DIV6 slices were biolistically transfected using a gene gun (Bio-Rad) , and cultures were imaged 3 d after transfection. Ten milligrams of gold particles (1.6 m in diameter; Bio-Rad) were coated with 90 g of shRNA plus 10 g of EGFP expression plasmids. Synaptic responses were evoked once every 5 s with a bipolar stimulus electrode placed in the stratum radiatum. The external recording solution consisted of the following (in mM): 2.5 CaCl 2 , 2.5 KCl, 1.3 MgCl 2 , 119 NaCl, 26 NaHCO 3 , 1 NaH 2 PO 4 , 11 glucose, 0.1 picrotoxin (PTX), and 0.001 tetrodotoxin, pH 7.4. The internal recording solution for the patch electrode consisted of the following (in mM): 115 cesium methanesulfonate, 20 CsCl, 10 HEPES, 2.5 MgCl 2 , 4 ATP disodium salt, 0.4 GTP trisodium salt, 10 sodium phosphocreatine, and 0.6 EGTA, pH 7.3. mEPSCs were recorded at Ϫ70 mV. CA1 pyramidal neurons expressing EGFP from the transfected slices were imaged directly in oxygenated aCSF containing 2.5 mM CaCl 2 and 1.3 mM MgCl 2 using an Olympus multiphoton system with a water-immersion 40ϫ objective (numerical aperture, 0.8; Olympus). Transfected CA1 pyramidal neurons were counted using fluorescence microscopy once every 12 h for 4 d after treatment with vehicle, AP5, or TTX. Two-way ANOVA was used to compare shH4_1-or shH4_2-transfected neurons to shLuc-transfected neurons.
Expression analysis. DIV 21 dissociated mouse hippocampal neurons in six-well plates were treated with vehicle, 100 M AP5, 0.1 M NVP-AAM077, or 1 M Ro25-4891 for 6 h in a cell culture incubator. Total RNA was isolated using the RNeasy Plus Kit (Qiagen). Agilent 4 ϫ 44 Mouse Arrays were used to measure the expression of individual transcripts. Statistical analyses were performed using R and Bioconductor software. Background correction of raw Agilent data was performed using the normexp function in the limma package using an offset of 50. Within-array normalization was performed using the normalizeWithinArrays function with the loess method. Last, arrays were normalized with the normalizeBetweenArrays function using the Aquantile method. Control probes were removed from the analysis. Data for duplicate probes on the Agilent array were averaged using the avereps function. Before comparison between groups, probes were filtered to ensure that only a single probe was represented for each gene using the featureFilter function with default parameters. Due to the small sample size in this analysis, variance filtering was not performed as this would likely have had an impact on the group comparisons performed using the limma package (Bourgon et al., 2010) . For gene ontology analysis, additional parameters were added during filtering to ensure that the universe of genes was limited to include only those genes with a particular gene ontology definition. Linear regression was performed using limma, and p values reported in the text as adjusted were corrected for multiple testing using the method of Benjamini and Hochberg (Benjamini and Hochberg, 1995) . Gene sets for genes altered after application of antagonists were specified using cutoffs of log fold-change of Ͼ0.5 and an adjusted p value of Ͻ0.05.
Gene set enrichment analysis was performed using the mRoast function in the limma package to test for enrichment of the AP5 gene sets in the NVP and Ro25 data. Gene ontology analysis was performed using the GOstats package with the gene universe defined as described above. Pathway analysis was performed using the Metacore package with default parameters (www.genego.com).
Results
Basal NMDAR activity maintains Erk1/2 and PSD-95 S295 phosphorylation NMDAR signaling was characterized in neuronal cultures under basal or stimulated conditions. Neuronal cultures were first treated with an NMDAR antagonist, AP5, followed by either vehicle or bath application of NMDA, to study NMDAR activity under basal or stimulated conditions, respectively. Bath application of NMDA activates both synaptic and extrasynaptic NMDARs (Hardingham and Bading, 2010) .
Under basal conditions, treatment of DIV 21 hippocampal neuronal cultures for 15 min with AP5, the broad NMDAR antagonist, resulted in a decrease in Erk1/2 phosphorylation (pErk1/2) and an increase in the phosphorylation of Ser-295 on PSD-95 (PSD-95 pS295; Fig. 1A , lanes 1 and 3, B, quantitation). Total protein levels of Erk1/2 and PSD-95 were not altered (Fig. 1 ). These data confirm that NMDARs are active under basal conditions in our neuronal cultures, and suggest that basal NMDAR activity maintains Erk phosphorylation and suppresses PSD-95 S295 phosphorylation.
Consistent with previous reports (Kim et al., 2007; Nelson et al., 2013) , treatment of DIV 21 hippocampal neuronal cultures for 15 min with vehicle followed by bath application of NMDA (70 M, for 10 min) resulted in a decrease in PSD-95 S295 phosphorylation (Fig. 1A, lanes 1 and 2, B) . The dephosphorylation of PSD-95 S295 was blocked by AP5 (Fig. 1A, lane 4) . The above data could reflect either that both synaptic and extrasynaptic NMDARs inhibit PSD-95 S295 phosphorylation, or that synaptic, but not extrasynaptic, NMDARs inhibit PSD-95 S295 phosphorylation.
Additionally, bath application of NMDA did not alter pErk1/2 (Fig. 1, lane 2) or affect the decrease in pErk1/2 induced by AP5 (Fig. 1, lanes 3 and 4) . This is consistent with previous data (Ivanov et al., 2006) and could be explained by the observation that bath application of NMDA activates both synaptic and extrasynaptic NMDARs (Hardingham and Bading, 2010) . As extrasynaptic and synaptic NMDARs have opposite effects on Erk1/2 phosphorylation, it would be reasonable that bath application of NMDA resulted in no significant change in Erk1/2 phosphorylation (Ivanov et al., 2006) . Together, these data indicate that there are differences between the downstream effects of basal and NMDA-induced NMDAR signaling.
Neuronal cultures were also treated with the GluN2A-preferring NMDAR antagonist, NVP (Auberson et al., 2002; Neyton and Paoletti, 2006) or the GluN2B-selective antagonist Ro25 (Fischer et al., 1997) . Under basal conditions, as seen with AP5, both of these subtype-selective antagonists increased PSD-95 S295 phosphorylation (Fig. 1A , lanes 5 and 7, B, quantification). However, unlike AP5, neither subtype-selective antagonist reduced the phosphorylation of Erk1/2 (Fig. 1) . Also, unlike AP5, neither NVP (0.1 M) nor Ro25 (1 M) blocked NMDA-induced dephosphorylation of PSD-95 S295 (Fig. 1A , lanes 5-8). The different effects of NVP and Ro25 versus AP5 could most simply be explained by the partial block of NMDARs by NVP and Ro25 versus the complete blockade by AP5.
Basal NMDAR activity regulates the expression of a set of genes that is overlapping but distinct from those regulated by stimulated NMDARs To characterize the downstream transcriptional targets of basal NMDAR activity, microarray analysis was performed on RNA isolated from DIV 21 cultured hippocampal neurons treated for 6 h with vehicle, AP5 (100 M), Ro25 (1 M), or NVP (0.1 M; Fig. 2 ). After treatment with AP5, 467 genes were significantly downregulated ( Fig. 2A, green is available from the National Center for Biotechnology Information with GEO ID GSE54708)]. Validation by quantitative RT-PCR (qRT-PCR) of a subset of gene expression changes identified from the microarray is shown in Figure 3A .
In contrast to AP5, no significant gene expression changes were observed by microarray after the treatment of neurons with either NVP or Ro25 (as with AP5, significant gene expression changes were defined using an adjusted p value of Ͻ0.05 and an absolute log 2 FC of Ͼ0.5). However, other data presented here indicated that both NVP (0.1 M) and Ro25 (1 M) significantly impacted phosphorylation of PSD-95 S295, and altered the mRNA expression level of some target genes (Figs. 1, 3A) . Therefore, we took a more sensitive approach by examining the overall effect of NVP and Ro25 on two sets of genes: all of the genes significantly upregulated by AP5, and all of those downregulated by AP5 ( Fig. 2A, red and green circles, respectively) . Notably, these aggregated gene sets were significantly altered after NVP or Ro25 treatment (Fig. 2 B, C ; NVP: up p ϭ 0.014, down p ϭ 0.008; Ro25: up p ϭ 0.008, down p ϭ 0.004). While the gene expression changes were generally smaller in magnitude after NVP or Ro25 treatment than after AP5 treatment, the direction of change observed with the aggregated gene sets was broadly consistent across all three treatments. These results suggest that the two subtype-selective NMDAR antagonists induce a similar but weaker transcriptional response compared with the broad antagonist AP5. As GluN2A-containing NMDARs are the predominant synaptic NMDARs in mature neurons, it is surprising the GluN2A-preferring antagonist NVP (at 0.1 M) did not induce robust gene expression changes similar to the broad antagonist AP5 (100 M). To test the hypothesis that the weak gene expression effect is due to insufficient blockade of GluN2A-NMDARs by 0.1 M NVP, we performed three different experiments.
First, we coapplied both Ro25 (1 M) and NVP (0.1 M) to neuronal cultures and measured the impact of this cotreatment on the expression of genes that were significantly altered by AP5 (Fig. 3A) . Interestingly, coapplication of NVP and Ro25 caused larger gene expression changes than those seen with either antagonist on their own, and, these changes were similar in magnitude to those seen by treatment with AP5 (Fig. 3A) . This is consistent with a model in which NVP (0.1 M) and Ro25 (1 M) have a weak effect on gene expression because individually they cause only partial, and largely nonoverlapping, inhibition of basal NMDAR signaling. (1 M) for 6 h. Fold change is normalized to vehicle. GAPDH was used as an internal control to normalize total mRNA level of each sample. C, Expression level of the selected mRNAs was measured by comparing their qRT-PCR circle times (CT) with GAPDH CT (Ϫ⌬CT is defined by the circle time of GAPDH minus the circle time of the gene of measurement). n ϭ 3-4 independent experiments. D, E, Western blot of apoptosis-related proteins from WT neurons treated with vehicle or AP5 for 6 h (D). Quantified in E. Error bars show SEM. *p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001, ****p Ͻ 0.0001, Student's t test. n ϭ 12 independent experiments. Second, we tested the effects of NVP at a higher concentration of 1 M. At this concentration, NVP is not specific for GluN2A receptors, and can block both GluN2A-and GluN2B-containing NMDARs (Neyton and Paoletti, 2006) . NVP at 1 M induced much larger gene expression changes than NVP at 0.1 M, and, these changes were similar in magnitude to those seen after AP5 treatment (Fig. 3A) . These data are also consistent with the idea that the weak effect of 0.1 M NVP is due to partial inhibition of NMDARs.
Third, we tested the NMDAR inhibitors on neurons from GluN2A KO mice (Kadotani et al., 1996) . In such neurons, Ro25-sensitive GluN2B containing diheteromeric NMDARs should be the predominant, if not the only, subtype of NMDAR present. Treatment of GluN2A KO cultures with Ro25 induced a similar pattern of gene expression changes as seen after treatment with the broad inhibitor AP5 (Fig. 3B) . Therefore, the weaker impact of Ro25 on gene expression regulation in WT cultures is likely because the predominant synaptic NMDARs are not Ro25-sensitive GluN2B-containing NMDARs in these cultures.
As NMDAR signaling is highly context dependent (Hardingham and Bading, 2010), we also compared the gene expression changes we observed after the inhibition of NMDARs in basal cultures with the changes in gene expression resulting from the activation of NMDARs by treatment of cultures of bicuculline. Similar to the methodology used above, two gene sets reflecting the genes upregulated or downregulated by activated NMDARs were generated by identifying bicuculline-induced gene expression changes that were blocked by AP5 (data from Zhang et al., 2007) . The behavior of these gene sets was analyzed in our microarray data from unstimulated neurons treated with AP5 (Fig. 2D , orange and blue dots, respectively). Importantly, the bicuculline-activated NMDAR upregulated gene set was significantly downregulated after AP5 treatment of basal cultures (Fig. 2D , orange dots; p ϭ 0.01), and the bicuculline-activated NMDAR downregulated gene set was significantly upregulated in our data after AP5 treatment (Fig. 2D , blue dots; p ϭ 0.002). These results suggest that there are individual genes that can be bidirectionally regulated by the inhibition or activation of NMDAR signaling. The 34 genes most significantly altered by both treatments are shown in Tables 2 and 3 . However, the majority of the genes significantly altered by AP5 were not significantly altered by bicuculline-induced activation of NMDARs ( Fig. 2E ; cutoff levels for significant changes are as defined above), suggesting that they are novel NMDAR-dependent genes that are specifically regulated by basal NMDAR activity. For instance, of 337 genes significantly upregulated by AP5 in basal conditions, only 9 were downregulated and 14 were upregulated by NMDAR activation in bicuculline conditions (Fig. 2E) .
Previous studies suggested that activation of synaptic NMDARs results in distinct gene expression differences compared with those seen after activation of extrasynaptic NMDARs (Zhang et al., 2007) . Therefore, the gene expression changes induced by AP5 in basal conditions were compared with those caused by activation of extrasynaptic NMDARs (defined by Zhang et al., 2007 as bath glutamate-induced gene expression changes that were blocked by AP5). While the extrasynaptic NMDAR downregulated gene set was modestly and significantly upregulated in our data after AP5 treatment ( p ϭ 0.05; Fig. 2F , blue dots), the extrasynaptic NMDAR upregulated gene set was not significantly downregulated in our data after AP5 treatment of basal cultures (Fig. 2F, orange dots) . Only seven genes were bidirectionally altered by both treatments with our cutoff thresholds (Fig. 2G) . Since the extrasynaptic NMDARregulated genes reflect a distinct downstream signaling pro- The 25 genes that were downregulated by AP5 (this study) and also upregulated by bicuculline-induced NMDAR activity (from Zhang et al., 2007) are shown. See also Figure 2E . The nine genes that were upregulated by AP5 (this study) and also downregulated by bicuculline-induced NMDAR activity (from Zhang et al., 2007) . See also Figure 2E .
cess than that seen with synaptic NMDAR-regulated genes, these data could be explained by the lack of extrasynaptic NMDAR activity under basal conditions.
Gene ontology and pathway analysis reveal enrichment of novel pathways in genes regulated by basal NMDAR activity Gene ontology analysis was used to highlight potential biological processes regulated by NMDAR basal activity. Within the most significant AP5-dependent gene expression changes, there was a significant over-representation of genes involved in several functions, including apoptosis, synaptic function, and class IIa HDACrelated pathways (Table 4) . Four of the top 21 AP5-affected pathways involved apoptosis ( Table 4 ), suggesting that basal NMDAR activity is linked to apoptotic pathways. In detail, components of intrinsic apoptotic pathways were enriched in the genes that were altered by AP5 ( p ϭ 9.0E-3, Fisher's exact test; Taylor et al., 2008) . These include significant upregulation of seven proapoptotic genes (Apaf1: log 2 FC ϭ 0.523, p ϭ 1.01E-3; Bid: log 2 FC ϭ 1.090, p ϭ 1.06E-7; Bim: log 2 FC ϭ 0.289, p ϭ 3.88E-2; Casp2: log 2 FC ϭ 0.434, p ϭ 1.22E-3; Hrk: log 2 FC ϭ 0.361, p ϭ 2.45E-2; Noxa: log 2 FC ϭ 1.060, p ϭ 5.22E-8; Puma: log 2 FC ϭ 0.574, p ϭ 3.40E-3) and downregulation of an anti-apoptotic gene (Bcl2: log 2 FC ϭ Ϫ0.287, p ϭ 3.67E-2). The identification of apoptosis-related pathways is consistent with the known role of synaptic NMDA receptor signaling in CREB-mediated neuronal survival (Hardingham et al., 2002) and anti-apoptotic gene expression changes (Lau and Bading, 2009; Léveillé et al., 2010) . We further tested whether these mRNA level changes correlated with protein level changes for four of these genes with log 2 FC Ͼ0.5 (Apaf1, Bid, Noxa, and Puma). Western blot analysis showed that AP5 treatment for 6 h significantly increased the protein levels of Apaf1 (FC ϭ 1.53 Ϯ 0.20, p ϭ 0.045), Bid (FC ϭ 1.24 Ϯ 0.08, p ϭ 0.017), and Noxa (FC ϭ 1.29 Ϯ 0.09, p ϭ 0.009; Fig. 3 D, E) . Puma expression increased following AP5 treatment, but this change did not reach statistical significance (FC ϭ 1.28 Ϯ 0.15, p ϭ 0.118). The expression of either a full-length or cleaved form of Casp3 was not changed by AP5 treatment (Casp3_F: FC ϭ 0.92 Ϯ 0.12, p ϭ 0.531; Casp3_C: FC ϭ 0.93 Ϯ 0.15, p ϭ 0.645), suggesting that NMDAR inhibition was not sufficient to trigger activation of apoptotic pathways in these neurons (Fig. 3 D, E) .
Four of the top 10 enriched gene ontology classes contain members of the class IIa HDAC family (Table 4) . HDACs are a class of enzymes that catalyze epigenetic histone modifications. Class IIa consists of HDAC4, HDAC5, HDAC7, and HDAC9, of which HDAC4, HDAC5, and HDAC9 are highly expressed in the brain (Haberland et al., 2009; Darcy et al., 2010) . Class IIa HDACs are known as transcriptional repressors associated with brain disorders, but their neuronal functions are unclear (Haberland et al., 2009; Williams et al., 2010; Li et al., 2012) . In our microarray results, HDAC4 was upregulated after AP5 treatment of neuronal cultures (log 2 FC ϭ 0.48, p ϭ 1.4E-2), and HDAC5 and HDAC9 were both downregulated (HDAC5: log 2 FC ϭ Ϫ0.57, p ϭ 3.1E-7; HDAC9: log 2 FC ϭ Ϫ0.86, p ϭ 9.9E-3; also see Table 1 ). qRT-PCR confirmed these changes showing that HDAC4 mRNA increased approximately twofold, while HDAC5 and HDAC9 fell by ϳ30% and ϳ50%, respectively (Fig. 4A) .
Class IIa HDAC expression and subcellular localization are controlled by NMDAR activity Protein levels of HDAC4 and HDAC5 were measured by Western blotting. HDAC4 was significantly increased by ϳ30% after AP5 treatment (p ϭ 0.007; Fig. 4B,D) ; HDAC5 protein levels fell with AP5, but the reduction did not reach significance (p ϭ 0.12; Fig.  4C,D) . The levels of HDAC4 and HDAC5 were also examined in the presence of TTX, which inhibits neuronal activity via blockade of action potentials. Treatment of neurons with TTX resulted in an ϳ1.7-fold increase in HDAC4 (p ϭ 0.043), and an ϳ0.6-fold decrease in HDAC5 (p ϭ 0.009). Lastly, levels of HDAC4 and HDAC5 were examined in neuronal cultures treated with PTX, a GABA A R antagonist that, like bicuculline, results in NMDAR activation (Hardingham et al., 2002) . PTX had no significant effect on either HDAC4 or HDAC5 protein levels (Fig. 4B-D) . This is consistent with previous reports in which stimulated NMDAR activity was not found to The ratio shows the number of genes that were significantly altered by AP5 divided by the total number of genes in that specific pathway. EMT, Epithelial-to-mesenchymal transition; GnRH, gonadotropin-releasing hormone; PKA, protein kinase A; GM-CSF, granulocyte macrophage colony-stimulating factor; PEDF, pigment epithelium-derived factor; MAG, myelin-associated glycoprotein; MEF2, myocyte enhancer factor 2. Y indicates that the pathway is related to either Synpase, Apoptosis, or HDAC.
affect mRNA expression of HDAC4, HDAC5, or HDAC9 (Zhang et al., 2007) . These data highlight that, while activation of NMDARs does not alter levels of HDAC4 or HDAC5 protein, inhibition of basal NMDAR signaling significantly alters both HDAC4 and HDAC5 protein levels. It has been reported that class IIa HDACs shuttle between the nucleus and cytoplasm in response to neuronal activity (Chawla et al., 2003; Bolger and Yao, 2005) . After transient transfection, C-terminal Flag-tagged HDAC4 and HDAC5 were present diffusely in the cytoplasm in hippocampal pyramidal neurons under basal conditions (Fig. 4 E, F ) . After 6 h of AP5 or TTX treatment, both HDAC4-Flag and HDAC5-Flag redistributed to the nucleus (Fig. 4E,F) . Additionally, immunostaining of endogenous HDAC4 after vehicle, AP5, PTX, or TTX treatment showed that, whereas there was only diffuse cytoplasmic staining of HDAC4 after vehicle or PTX treatment, both TTX and AP5 induced strong nucleus-localized HDAC4 staining (Fig. 4G) , which is consistent with previous data (Chawla et al., 2003; Sando et al., 2012) .
The elevated expression of HDAC4 in response to AP5 treatment suggested that HDAC4 might be an important signaling component in low NMDAR activity conditions. Therefore, we generated two different shRNAs targeting HDAC4 (shH4_1 and shH4_2) to investigate its endogenous function. Both shRNAs were effective in knocking down protein levels of Flag-HDAC4 heterologously expressed in HEK293 cells (Fig. 5A) . A lentiviral vector was used to express shH4_1 (shH4_1-lentivirus) or control shRNA (targeting firefly luciferase; shLuc-lentivrus) in dissociated hippocampal cultures. Additionally, Synapsin promoter-driven GFP was included in the lentiviral vectors to enable identification of infected neurons. One week after infection, a majority of neurons expressed GFP, indicating a high efficiency of infection (Fig.  5B) . In control shLuc-lentivirus-infected cultures, faint cytoplasmic immunofluorescence marking endogenous HDAC4 was observed under basal conditions. After 6 h of AP5 or TTX treatment, anti-HDAC4 immunofluorescence revealed a strong nuclear signal in control shLuc-lentivirus-infected cultures (Fig. 5C,D) . The AP5-or TTX-induced nuclear signal of HDAC4 was abolished by infection with the shH4_1-lentivirus (Fig. 5C,D) , indicating that the signal represents endogenous HDAC4. Together, these experiments show that in conditions of neuronal hypoactivity and/or NMDAR blockade, HDAC4 is endogenously induced at the mRNA and protein levels, and that the protein accumulates in the nucleus.
HDAC4 is required for AP5 suppression but not PTX induction of a set of genes Because HDAC4 is a known transcriptional repressor (Haberland et al., 2009; Sando et al., 2012) , we hypothesized that HDAC4 contributes to the altered gene expression pattern induced by AP5 treatment of cultured neurons. To address this, gene expression changes resulting from AP5 treatment were examined in the presence or absence of HDAC4. Infection of neurons with shH4_1-lentivirus suppressed HDAC4 mRNA (Fig. 5E, shH4_1 vehicle), confirming the efficacy of shH4_1 in neurons. Treatment of neurons with AP5 for 6 h resulted in a decrease in the expression of BDNF, HDAC5, NPAS4, Nr4a2, Nr4a3, and Ptgs2 (Fig. 5E ). However, in neuronal cultures infected with shH4_1-lentivirus, AP5 had no effect on HDAC5 expression and had a significantly weaker effect on the suppression of BDNF, Nr4a2, and Ptgs2 (Fig. 5E, black bars) . shH4_1-lentivirus did not affect the AP5-induced decrease in expression of NPAS4 or Nr4a3; nor did it alter the basal expression of any of the genes examined here (Fig. 5E ). The induction of BDNF, NPAS4, Nr4a2, Nr4a3, and Ptgs2 mRNAs by PTX was unchanged by HDAC4 knockdown (Fig. 5F ). Together, these data indicate that HDAC4 plays an important role in the suppression of a subset of genes by AP5, but is not involved in baseline or PTX induction of those genes. HDAC4 is required for neuronal survival under low NMDAR activity HDAC4 was shown to function as a transcriptional repressor and to play a role in regulating excitatory synapses (Haberland et al., 2009; Sando et al., 2012 ). Therefore, we tested whether HDAC4 knockdown altered excitatory synaptic transmission. In pyramidal neurons of organotypic hippocampal slice cultures, the expression of shH4_1 for 5 d did not alter the frequency or amplitude of mEPSCs, compared with either neighboring untransfected neurons or neurons expressing control shLuc (Fig. 6A-C) . These data are consistent with a previous report and argue that, at least under basal conditions, endogenous HDAC4, which is largely absent from the nucleus in these circumstances, has little effect on excitatory synaptic function.
Because HDAC4 most likely functions in the nucleus (Fig. 5; Haberland et al., 2009) , and HDAC4 is induced and redistributed to nuclei when NMDAR activity is inhibited, we next studied the effects of HDAC4 knockdown in neurons treated with TTX or AP5. Neurons expressing shH4_1 or shH4_2 appeared similar to neurons expressing shLuc under basal conditions (Fig. 7 A, C, vehicle) . However, ϳ20% of shH4_1-transfected neurons disappeared after 2 d of TTX treatment, and ϳ80% of the shH4_1-transfected neurons were either fragmented or disappeared after 3 d of TTX treatment (Fig. 7B , examples of healthy looking shLuc transfected neurons and fragmented shH4_1 or shH4_2 transfected neurons after 3 d TTX treatment). In contrast, control shLuctransfected neurons showed much better survival: ϳ80% remained alive after up to 4 d of TTX treatment (Fig. 7 B, C) . More than 90% of shH4_1-and shLuc-transfected neurons remained alive for up to 4 d in control basal conditions (vehicle treatment; Fig. 7C ). Like TTX, AP5 caused a significant, albeit less severe, death of neurons transfected with shH4_1 (Fig.  7C) . Similar results were obtained with a different HDAC4 shRNA (shH4_2; Fig.  7B ,C). These findings indicate that HDAC4 is required for neuronal survival under conditions of chronic low neuronal activity (TTX) or absence of basal NMDAR activity (AP5).
To investigate the underlying mechanism of the neuroprotective role of HDAC4, we measured the effect of HDAC4 knockdown on mRNA expression of apoptosisrelated genes in neurons after AP5 or vehicle treatment. Consistent with the microarray data, AP5 treatment significantly enhanced the expression of Apaf1, Bid, Noxa, and Puma in control shLucexpressing neurons (Fig. 7D) . Knockdown of HDAC4 did not alter the baseline expression of these apoptosis-related genes ("shH4 Veh"), but it caused a greater increase in their expression following AP5 treatment (Fig. 7D , compare "shH4 AP5," "shLuc AP5"). This suggests that HDAC4 is required to suppress expression of these apoptosis-related genes when NMDAR activity is blocked by AP5, likely contributing to its neuroprotective effects. . White arrows indicate cell bodies. C, Percentage survival of CA1 pyramidal neurons transfected with shLuc, shH4_1, or shH4_2 after vehicle, AP5, or TTX treatment for the indicated times. D, Changes in mRNA levels of a panel of apoptosis-related genes were measured after AP5 (100 M) treatment for 6 h from lentivirus (shLuc or shH4)-infected dissociated hippocampal neurons. The fold change is normalized to vehicle. GAPDH was used as an internal control to normalize the mRNA level of each gene. Error bars indicate the SEM. *p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ0.001, ****p Ͻ0.0001, two-way ANOVA. n ϭ 4 -5 independent experiments.
